title: [Early prevention of experimental left ventricular hypertrophy in experimental hypertension and angiotensin II levels].
abstract: BACKGROUND
  Angiotensin II levels can be partially inhibited during chronic administration of angiotensin converting enzyme (ACE) inhibitors, limiting from a clinical point of view its efficacy in the treatment of hypertension. There are few studies relating ACE activity directly with early prevention of left ventricular hypertrophy (LVH) in systemic hypertension during the administration of an ACE inhibitor (ACEI).
  
  
  OBJECTIVE
  To evaluate the effects of early ACE inhibition with perindopril on the development of hypertension, LVH and levels of angiotensin II (Ang II) in plasma as well as in LV in the rat Goldblatt model (Gb; 2 kidneys-1 clip), 2 weeks after surgery.
  
  
  RESULTS
  Systolic blood pressure and relative LV mass increased by 42% and 20% respectively, in the Gb group (p < 0.001). Plasma and LV ACE activities were significantly higher in the Gb rats compared with the control rats. Plasma and LV Ang II levels also increased by 129% and 800%, respectively. Perindorpil prevented hypertension and LVH development by inhibiting plasma ACE (and also LV ACE), and also circulation Ang II in plasma and in the LV.
  
  
  CONCLUSIONS
  In this experimental model of hypertensive LVH, there is an early activation of plasma and cardiac ACE. Early administration of an ACE inhibitor prevents the development of hypertension and LVH by inhibiting the increases of plasma and LV Ang II.
authors.affiliation: Departamento de Bioquímica y Biología Molecular, Facultad de Química y Farmacia, Universidad de Chile, Santiago, Chile.
authors.forename: A
authors.initials: A
authors.lastname: Gálvez
authors.forename: M P
authors.initials: MP
authors.lastname: Ocaranza
authors.forename: S
authors.initials: S
authors.lastname: Lavandero
authors.forename: J E
authors.initials: JE
authors.lastname: Jalil
mesh_terms: D000804:Angiotensin II / Q000032:analysis / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical; D006973:Hypertension / Q000150:complications* / Q000201:enzymology; D017379:Hypertrophy, Left Ventricular / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000032:analysis / Q000097:blood; D020913:Perindopril / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A; D020913:Perindopril